Oncotarget is a peer-reviewed free-access bio-medical journal that publishes a variety of articles within and beyond oncology. Established in 2010, Oncotarget has an impact factor of 5.16 (according to 2016 ratings). Its editors in chief are Mikhail Blagosklonny and Andrei V.Gudkov.
Additionally, this international peer-reviewed journal has a lense on the pathological origin of all cancer types, possible targets for therapies and treatment procedures used to manage the conditions of cancer patients. More succinctly, this high impact journal also focuses on the effect of various cancer management programs as well as emerging therapeutic agents and modus operandi. Check Oncotarget at scimagojr.com
Oncotarget promotes the use of fundamental clinical sciences to round diseases. Under the governance of leading scientists, this journal has assisted researchers from all walks of life to contribute to the advancement of biomedical sciences.
One of the signature articles in Onco Targets and therapy an article by Huang. Liu Chen and Shao which was about Tripple Negative Breast Cancer (TNBC) where they established the role of cisplatin and carboplatin combining them with paclitaxel as the neoadjuvant regiment for TNBC.
In September 2017. PR Newswire reported that Oncotarget will be published twice a week and that their publications will be available in PubMed and other highly ranked indexes and archives in scientific research. Further, it was reported that the eminent biomedical journal would continue with its presence on PubMed, PubMed Central and the various web of sciences such as Scopus.
Since its inception, this journal has published seven volumes, 324 issues and currently working on its eighth volume. Oncotarget gives each of its articles a Direct Object Identifier (DOI) and abides by recommendations of Committee on Publication Ethics (COPE).
The journal of scientists prides on disseminating well-regarded biomedical research aimed at addressing the challenges of the 21st century, conjointly working to see to it that human beings in a world free of diseases. It sounds as if it is a distant dream, but if their research is anything to go by then, this will soon come to pass. This journal reconnoiters the realities behind new and prevailing therapies and improving outcomes. Follow Oncotarget journal on Twitter.